Prognostic relevance of Centromere protein H expression in esophageal carcinoma by Guo, Xian-Zhi et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Cancer
Open Access Research article
Prognostic relevance of Centromere protein H expression in 
esophageal carcinoma
Xian-Zhi Guo†1,2,6, Ge Zhang†5, Jun-Ye Wang3, Wan-Li Liu1,2, Fang Wang4, Ju-
Qin Dong1,2, Li-Hua Xu1,2, Jing-Yan Cao1,2, Li-Bing Song1,2 and Mu-
Sheng Zeng*1,2
Address: 1State Key Laboratory of Oncology in Southern China, Sun Yat-sen University Cancer Center, Guangzhou, PR China, 2Department of 
Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, PR China, 3Thoracic Carcinoma, Sun Yat-sen University Cancer Center, 
Guangzhou, PR China, 4Pathology, Sun Yat-sen University Cancer Center, Guangzhou, PR China, 5School of Pharmaceutical Sciences, Sun Yat-
sen University, Guangzhou, PR China and 6The Central Hospital of Xuhui District, Shanghai, PR China
Email: Xian-Zhi Guo - guoxianzhi1226@hotmail.com; Ge Zhang - zhangge@mail.sysu.edu.cn; Jun-Ye Wang - jyewang@126.com; Wan-
Li Liu - wanliliu@126.com; Fang Wang - wangfang200366@sohu.com; Ju-Qin Dong - djq3m@163.com; Li-Hua Xu - xlhua325@126.com; Jing-
Yan Cao - jingyan_cao@hotmail.com; Li-Bing Song - songlib2000@yahoo.com; Mu-Sheng Zeng* - zengmsh@mail.sysu.edu.cn
* Corresponding author    †Equal contributors
Abstract
Background: Many kinetochore proteins have been shown to be associated with human cancers.
The aim of the present study was to clarify the expression of Centromere protein H (CENP-H),
one of the fundamental components of the human active kinetochore, in esophageal carcinoma and
its correlation with clinicopathological features.
Methods: We examined the expression of CENP-H in immortalized esophageal epithelial cells as
well as in esophageal carcinoma cells, and in 12 cases of esophageal carcinoma tissues and the
paired normal esophageal tissues by RT-PCR and Western blot analysis. In addition, we analyzed
CENP-H protein expression in 177 clinicopathologically characterized esophageal carcinoma cases
by immunohistochemistry. Statistical analyses were applied to test for prognostic and diagnostic
associations.
Results: The level of CENP-H mRNA and protein were higher in the immortalized cells, cancer
cell lines and most cancer tissues than in normal control tissues. Immunohistochemistry showed
that CENP-H was expressed in 127 of 171 ESCC cases (74.3%) and in 3 of 6 esophageal
adenocarcinoma cases (50%). Statistical analysis of ESCC cases showed that there was a significant
difference of CENP-H expression in patients categorized according to gender (P = 0.013), stage (P
= 0.023) and T classification (P = 0.019). Patients with lower CENP-H expression had longer overall
survival time than those with higher CENP-H expression. Multivariate analysis suggested that
CENP-H expression was an independent prognostic marker for esophageal carcinoma patients. A
prognostic value of CENP-H was also found in the subgroup of T3~T4 and N0 tumor classification.
Conclusion:  Our results suggest that CENP-H protein is a valuable marker of esophageal
carcinoma progression. CENP-H might be used as a valuable prognostic marker for esophageal
carcinoma patients.
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Background
During the proliferation of normal cells, the centrosome
ensures the equal segregation of chromosomes to the
postmitotic daughter cells by organizing the bipolar
mitotic spindle. In contrast, in cancer cells multipolar
mitotic spindles and various centrosomal anomalies, such
as supernumerary centrosomes, centrosomes of abnormal
size and shape, and prematurely split centrosomes are fre-
quently observed [1-3] It is conceivable that such abnor-
malities disrupt normal chromosomal segregation,
producing aneuploid cells and causing chromosomal
instability (CIN).
CIN has been recognized as a hallmark of human cancer
and is caused by continuous chromosome missegregation
during mitosis[4]. Proper chromosome segregation
requires a physical connection between spindle microtu-
bules and centromeric DNA and this attachment occurs at
proteinaceous structures called kinetochore [5]. Several
kinetochore proteins have been identified in humans, and
the list of kinetochore associated proteins continues to
grow, including centromere protein (CENP)-A, CENP-B,
CENP-C, CENP-E, CENP-F, CENP-H, CENP-I, and
INCENP [6,7]. Studies have shown that kinetochore mal-
function is a major cause of aneuploidy and is closely
associated with CIN [8,9]. Normal expression of core
kinetochore components is essential to prevent chromo-
some instability [10]. CENP-H was initially identified as a
component of the mouse centromere [11]. Human CENP-
H protein was recently isolated and shown to localize in
the inner plate together with CENP-A and CENP-C and is
a fundamental component of the active centromere com-
plex [12,13]. Studies using budding yeast have shown that
a molecular core consisting of CENP-A, CENP-C, CENP-
H, and Ndc80/HEC plays a central role in linking centro-
meres to the spindle microtubule [14].
Recent research has shown that CENP-H is up-regulated in
most colorectal cancers, and ectopic expression of CENP-
H induces chromosome missegregation and aneuploidy
in diploid cell lines [15]. Another study found significant
association between the level of CENP-H mRNA expres-
sion and clinical stage in oral squamous cell carcinomas
and indicated that human CENP-H was closely linked to
the increased or abnormal cell proliferation in malignant
conditions [16]. Previously, we have demonstrated a cor-
relation between expression of CENP-H and both tumor
progression and poor prognosis of the patients in the
human nasopharyngeal carcinoma[17]. Although CENP-
H may play an important role in chromosome instability
and carcinogenesis, there are no reports on its role in tum-
origenesis and progression of esophageal carcinoma. In
this study, we thus investigated the CENP-H expression
and its clinical significance in human esophageal carci-
noma.
Methods
Cell lines
The NE-3 and 108CA cell lines were obtained from Dr. Jin
(the University of Hong Kong, P. R. China) and were cul-
tured in Keratinocyte-SFM (Invitrogen, Carlsbad, CA) sup-
plemented with antibiotics (100 μg/μL streptomycin and
100  μg/μL penicillin). The NE-3 is an immortalized
esophageal epithelial cell lines and the latter is an ESCC
cell line[18,19]. The ESCC cell lines Eca-109, TE-1, and
Kyse140 (Cell Bank of Type Culture Collection of Chinese
Academy of Sciences, Shanghai, China) were grown in
RPMI 1640 (Invitrogen) supplemented with 10% fetal
bovine serum, 100 μg/μL streptomycin, and 100 μg/μL
penicillin in a humidified incubator containing 5% CO2
at 37°C.
Patients and tissue specimens
Twelve pairs of ESCC tissue specimens and corresponding
nontumorous specimens were obtained from patients
with ESCC who underwent surgical esophageal tissue
resection at the Cancer Center of Sun Yat-sen University
(Guangzhou, P. R. China) during 2007. Written informed
consent was obtained from each patient before surgery.
All excised samples were obtained within 1 h after the
operation from tumor tissues and corresponding nontu-
morous tissues 5–10 cm from the tumor. All excised tis-
sues were immediately placed in liquid nitrogen until
further analysis. In addition, immunohistochemstry anal-
ysis was conducted on 177 paraffin-embedded samples,
including 171 ESCC and 6 esophageal adenocarcinoma
which were histologically and clinically diagnosed from
the Cancer Center, Sun Yat-sen University, between 2001
and 2004. Prior to the use of these clinical materials for
investigation, informed consent from patients and
approval from the Institute Research Ethics Committee
were obtained. Primary cancers of the esophagus were
classified according to the pathological TNM classification
[20]. Since the number of esophageal adenocarcinoma is
small, clinical information of 171 ESCC samples is only
described in detail in Table 1. Patients included 129 males
and 42 females, of ages ranging from 33 to 82 years
(mean, 56.7 years). The figures on metastasis pertain to its
presence at any time in follow-up. The median follow-up
time for overall survival was 25.0 months for patients still
alive at the time of analysis, and ranged from 1 to 78
months. A total of 112 (65.5%) patients died during fol-
low up.
RNA extraction and reverse transcription-PCR
Total RNAs from cells, tumor tissue and nontumorous tis-
sues was extracted using Trizol reagent (Invitrogen)
according to the manufacturer's instructions. The RNA
was pretreated with DNase and used for cDNA synthesis
with random hexamers. The full-length open reading
frame of CENP-H was PCR amplified from cDNA samplesBMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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of normal tissue and ESCC cell lines. The following prim-
ers were used for amplification of CENP-H: sense primer,
5'-TGCAAGAAAAGCAAATCGAA-3'; antisense primer, 5'-
ATCCCAAGATTCCTGCTGTG-3'. Glyceraldehyde-3-phos-
phate dehydrogenase was amplified as an internal control
using sense primer, 5'-AATCCCATCACCATCTTCCA-3'
and antisense primer, 5'-CCTGCTTCACCACCTTCTTG-3'.
The appropriate size of PCR products was confirmed by
agarose gel electrophoresis.
Protein extraction and immunoblotting
Frozen tissue samples were solubilized in lysis buffer [7
mol/L urea, 2 mol/L thiourea, 2% CHAPS, 0.1 mol/L DTT,
0.1% NP40, 40 mmol/L Tris-HCl] using a Polytron
homogenizer following centrifugation (100,000 g) for 1 h
at 4°C. Cultured cells were harvested in 1× SDS sample
buffer [62.5 mmol/L Tris-HCl (pH 6.8), 2% SDS, 10%
glycerol, and 5% 2-mercaptoethanol] and were heated for
5 min at 100°C. Protein concentration was determined by
Table 1: Clinicopathologic characteristics of patient samples and expression of CENP-H in esophageal carcinoma.
Characteristics n(%)
(n = 171)
Gender
Male 129(75.4)
Female 42(24.6)
Age(y)
≥ 60 103(60.2)
<60 68(39.8)
Stage
I 10(5.8)
II a 75(43.9)
II b 14(8.2)
III 63(36.8)
IV 9(5.3)
Histological classification
Squamous cell carcinoma 171(100.0)
Histological differentiation
Well 55(32.2)
Moderate 72(42.1)
Poor 44(25.7)
Tumor diameter
≥ 40 mm 72(42.1)
<40 mm 99(57.9)
Depth of invasion
Submucosa 12(7.0)
Muscularis propria 58(33.9)
Adventitia 101(59.1)
pT classification
T1 13(7.6)
T2 46(26.9)
T3 106(62.0)
T4 6(3.5)
pN classification
YES 77(45.0)
NO 94(55.0)
pMetastasis
YES 9(5.3)
NO 162(94.7)
Vital status(at follow-up)
Alive 59(34.5)
Death because of esophageal carcinoma 109(63.7)
Death because of unknown cancer or other than esophageal carcinoma 3(1.8)
Expression of CENP-H
Negative 44(25.7)
Positive 127(74.3)
Low expression 54(31.6)
High expression 73(42.7)BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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the Bradford assay (Bio-Rad Laboratories, Hercules, CA).
Equal amounts of proteins were separated electrophoreti-
cally on 12% SDS polyacrylamide gels and transferred
onto polyvinylidene difluoride membranes (Amersham
Pharmacia Biotech, Piscataway, NJ). The membrane was
probed with an anti-CENP-H rabbit polyclonal antibody
(1:1,000; Bethyl Laboratories, Montgomery, TX). Expres-
sion of CENP-H was determined with horseradish peroxi-
dase-conjugated anti-rabbit immunoglobulin G (1:3,000;
Amersham Pharmacia Biotech) and enhanced chemilu-
minescence (Amersham Pharmacia Biotech) according to
the manufacturer's suggested protocols. An anti-α-tubulin
mouse monoclonal antibody (1:1,000; Santa Cruz Bio-
technology, Santa Cruz, CA) was used to confirm equal
loading.
Immunohistochemistry
Immunohistochemistry was done to study altered protein
expression in 177 human esophageal cancer tissues. In
brief, paraffin-embedded specimens were cut into 4-μm
sections and baked at 65°C for 30 min. The sections were
deparaffinized with xylenes and rehydrated. Sections were
submerged into EDTA antigenic retrieval buffer and
microwaved for antigenic retrieval. The sections were
treated with 3% hydrogen peroxide in methanol to
quench the endogenous peroxidase activity, followed by
incubation with 3% bovine serum albumin to block the
nonspecific binding. Rabbit polyclonal anti-CENP-H
(1:500; Bethyl Laboratories) was incubated with the sec-
tions overnight at 4°C. For negative controls, the primary
antibody was replaced by normal rabbit serum. After
washing, the tissue sections were treated with biotinylated
anti-rabbit secondary antibody (Zymed, San Francisco,
CA), followed by further incubation with streptavidin
horseradish peroxidase complex (Zymed). The tissue sec-
tions were immersed in 3-amino-9-ethyl carbazole and
counterstained with 10% Mayer's hematoxylin, dehy-
drated, and mounted in Crystal Mount. The degree of
immunostaining of formalin-fixed, paraffin-embedded
sections was reviewed and scored by two independent
observers. The proportion of the stained cells and the
extent of the staining were used as criteria of evaluation.
For each case, at least 1,000 tumor cells were analyzed and
the percentage of positively nuclear stained tumor cells
was recorded. For each sample, the proportion of CENP-
H-expressing cells varied from 0% to 100%, and the inten-
sity of nuclear staining varied from weak to strong. One
score was given according to the percent of positive cells
as: < 5% of the cells:1 point; 6–35% of the cells:2 point;
36–70% of the cells:3 point; >71% of the cells: 4 point.
Another score was given according to the intensity of
staining as negative staining: 1 point; weak staining (light
yellow): 2 point; moderate staining(yellowish brown): 3
point; and strong staining(brown): 4 point. A final score
was then calculated by multiple the above two scores. If
the final score was equal or bigger than four, the tumor
was considered high expression; otherwise, the tumor was
considered low expression [21].
Statistical analysis
Since the number of esophageal adenocarcinoma is small,
all statistical analyses were carried out in 171 ESCC cases
using the SPSS 13.0 statistical software package. Mann-
Whitney  U  test was used to analyze the relationship
between CENP-H expression and clinicopathologic char-
acteristics. Survival curves were plotted by the Kaplan-
Meier method and compared by the log-rank test. The sig-
nificance of various variables for survival was analyzed by
the Cox proportional hazards model in the multivariate
analysis. P < 0.05 in all cases was considered statistically
significant.
Results
Expression of CENP-H in esophageal carcinoma cell lines
To investigate the expression levels of CENP-H transcripts
and protein in esophageal cancer cell lines, semiquantita-
tive reverse transcription-PCR analysis and Western blot-
ting analysis were done in NE-3, 108CA, Eca-109, TE-1,
and Kyse140 cell lines. All five cell lines showed higher
level expression of CENP-H mRNA in comparison with
the normal esophageal tissue (Fig. 1). Western blotting
analysis showed that CENP-H protein was highly
expressed in all cell lines, whereas it was weakly detected
in normal esophageal tissue (Fig. 1).
Expression analysis of CENP-H mRNA and protein in an  esophageal immortalization cell line (NE3) and 4 esophageal  carcinoma cell lines 108CA, Kyse 140, Eca-109 and TE-1 by  reverse transcription-PCR and Western blotting Figure 1
Expression analysis of CENP-H mRNA and protein in 
an esophageal immortalization cell line (NE3) and 4 
esophageal carcinoma cell lines 108CA, Kyse 140, 
Eca-109 and TE-1 by reverse transcription-PCR and 
Western blotting. A normal esophageal tissue was used as 
a control.BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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Expression of CENP-H in paired esophageal cancer and 
nontumorous tissues
As we detected CENP-H overexpression in esophageal car-
cinoma cell lines, we were interested in investigating the
status of CENP-H expression in esophageal carcinoma
biopsies. We initially did RT-PCR analysis on twelve
esophageal tumor tissues (T) versus normal esophageal
tissues (N) obtained from the same patients. The expres-
sion of GAPDH was examined as an internal control. As
shown in Fig 2A, the expression levels of CENP-H mRNA
in most cancer tissues (6/12) was higher than in normal
tissues, and quantitative analysis showed that there was a
significant difference in CENP-H expression between can-
cer tissues and normal tissues. To determine if the higher
level of CENP-H mRNA expression revealed by RT-PCR
analysis was directly linked to increased levels of CENP-H
protein expression, we performed Western blot analysis
with protein extracts from matched samples of tumor (T)
and adjacent normal tissue (N) (from which the mRNA
samples were extracted). As shown in Fig 2B, CENP-H was
found to be greatly overexpressed in 8 of 12 cases of pri-
mary esophageal carcinoma, whereas only faint CENP-H
expression was found in the normal esophageal tissues,
with at least twofold overexpression of CENP-H in cancer
tissues compared with normal tissues in these 8 cases (the
density ratio was from 2.3270 to 51.735) (Fig 2C). There
was no significant difference in other four pairs of esopha-
geal carcinoma biopsies, which showed low expression of
CENP-H in both normal and tumor tissues (Data not
shown). Taken together, these data demonstrate that
CENP-H is highly expressed at both mRNA and protein
levels in most of the esophageal cancer tissues. However,
the inconsistent expression of CENP-H at mRNA and pro-
tein levels for case 2 and 5 indicate that the deregulation
of CENP-H could happen at either transcriptional or post-
transcriptional stage.
Expression of CENP-H in archival esophageal cancer 
tissues
Expression and subcellular localization of CENP-H pro-
tein was determined by immunohistochemistry in 177
paraffin-embedded, archival esophageal cancer tissues.
CENP-H protein was detected in 127 of 171 ESCC
cases(74.3%) and in 3 of 6 esophageal adenocarcinoma
cases (50%). The subcellular location of CENP-H was
nuclei and cytoplasm of tumor cells, but mainly nuclei. In
addition, diffuse staining was observed in some tumor
cells (Fig. 3C to 3H). Fig. 3C and 3D showed low expres-
sion of CENP-H in esophageal carcinoma tissues, and Fig.
3E and 3F showed high expression of CENP-H located in
nuclei in esophageal carcinoma tissues. Fig. 3G and 3H
showed high expression of CENP-H located in mainly
nuclei and partly cytoplasm in esophageal carcinoma tis-
sues. No specific CENP-H staining was observed in nor-
mal esophageal epithelial cells (Fig. 3A and 3B) and in the
surrounding stroma cells.
Correlation between CENP-H protein expression and 
clinicopathological features
Table 2 shows the relationship between the expression of
CENP-H protein and clinical characteristics in 171 ESCC
cases. There was no significant correlation between the
expression level of CENP-H protein and age, histological
classification, histological differentiation, tumor diame-
ter, depth of invasion, pN classification or distant metas-
tasis of esophageal cancer patients. However, the
expression of CENP-H is closely associated with stage of
esophageal cancer patients (P = 0.023) and T classification
(P = 0.019) The expression of CENP-H protein was posi-
tively correlated with staging and T classification (Table
2). Higher staging and T classification correlated with
higher CENP-H expression. In addition, there was a signif-
icant difference of CENP-H expression in patients catego-
rized according to gender (P = 0.013). The expression of
CENP-H protein in male patients was higher than in
female patients.
Survival analysis
Kaplan-Meier analysis and the log-rank test were used to
calculate the effect of classic clinicopathological character-
istics (including gender, stage, N classification) and
CENP-H expression on survival. The expression level of
CENP-H protein in esophageal carcinoma was signifi-
cantly correlated with patients' survival time (P < 0.001),
indicating that higher levels of CENP-H expression was
correlated with shorter survival time. The low CENP-H
expression group had better survival, whereas the high
CENP-H expression group had shorter survival (Fig. 4).
The median survival of patients with high CENP-H expres-
sion was much shorter (19 months) than those with low
CENP-H expression (33 months) (P < 0.001, Log-rank).
In addition, N classification, stage and gender were also
significantly correlated with survival in Kaplan-Meier
analysis and log-rank test (for N classification, P < 0.001;
for stage, P = 0.039 and for gender, P = 0.005). We did
multivariate survival analysis, which included CENP-H
expression level, stage, N classification and gender, to
determine if CENP-H expression level is an independent
prognostic factor of outcomes. In this analysis, N classifi-
cation and CENP-H expression were recognized as inde-
pendent prognostic factors (Table 3). Thus, our findings
indicate that CENP-H protein expression level has a sig-
nificant correlation with prognosis of esophageal carci-
noma.
We also analyzed the prognostic value of CENP-H expres-
sion in selective patient subgroups stratified according to
the stage, T and N classification, respectively. Patients withBMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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Expression analysis of CENP-H mRNA and protein in normal esophageal tissues and esophageal carcinoma cancer tissues by  reverse transcription PCR (A) and Western blots (B) Figure 2
Expression analysis of CENP-H mRNA and protein in normal esophageal tissues and esophageal carcinoma 
cancer tissues by reverse transcription PCR (A) and Western blots (B). A. Reverse transcription PCR results in 8 
pairs of esophageal tissues. B. Western blots results in 8 pairs of esophageal tissues. (N means normal and T means tumor). C. 
The density ratio of western blots results by Quantity one.BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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Expression analysis of CENP-H protein by immunohistochemistry Figure 3
Expression analysis of CENP-H protein by immunohistochemistry. CENP-H expression was mainly localized within 
nuclei of tumor cells, and diffuse staining was observed in some tumor cells. CENP-H is not expressed in normal epithelial cells. 
A and B Staining of CENP-H in normal esophageal epithelial tissue (arrow, normal epithelial cells). C and D, low expression of 
CENP-H in esophageal carcinoma tissues (200 and 400, respectively). E, F, G and H, high expression of CENP-H in esophageal 
carcinoma tissues (200 and 400, respectively).BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
Page 8 of 13
(page number not for citation purposes)
tumors exhibiting high CENP-H expression had signifi-
cantly shorter overall survival compared with patients
with low expression of CENP-H in the T3–T4 subgroup (n
= 112; log-rank, P = 0.001; Fig. 5B) and the N0 subgroup
(n = 94; log-rank, P = 0.007; Fig. 5C). A similar analysis of
the T1–T2 subgroups (n = 59; log-rank, P = 0.115; Fig. 5A)
and the N1 subgroup (n = 77; log-rank, P = 0.054; Fig. 5D)
did not show statistically significant differences between
patients with low or high levels of CENP-H expression.
Discussion
In this report, we presented the first evidence that a kine-
tochore protein, CENP-H, was overexpressed at both
mRNA and protein levels in immortalized cells, ESCC cell
lines and most esophageal carcinoma tissues. Overexpres-
sion of CENP-H protein was also frequently observed in
ESCC specimens and correlated with several aspects of
tumor progression summarized in the tumor-node-metas-
tasis classification.
The expression of CENP-H in various kinds of malignant
tumors has been reported [14]. However, only a few
reports, including our previous article, showed the prog-
nostic relevance of CENP-H expression in neoplasms.
Tomonaga et al. [15] first reported that up-regulation of
CENP-H was occurred in primary human colorectal can-
cer tissues as well as in CIN tumor cells. Shigeishi et al.
[16] reported that the expression level of CENP-H mRNA
was significantly higher in oral squamous cell carcinomas
than normal gingivae and found a significant association
between the level of expression of CENP-H mRNA and
clinical stage in oral squamous cell carcinomas. Our pre-
vious study [17] showed that the expression level of
CENP-H was higher in nasopharyngeal carcinoma cell
Table 2: Correlation between the clinicopathologic features and expression of CENP-H protein
CENP-H
Characteristics Low expression High expression P
Gender
Male 67(51.9) 62(48.1) 0.013
Female 31(73.8) 11(26.2)
Age(y)
≥ 60 58(56.3) 45(43.7) 0.747
<60 40(58.8) 28(41.2)
Stage
I 9(90.0) 1(10.0)
II a 46(61.3) 29(38.7)
II b 9 (64.3) 5(35.7) 0.023*
III 30(47.6) 33(52.4)
IV 4(44.4) 5(55.6)
Histological differentiation
Well 30(54.5) 25(45.5)
Moderate 42(58.3) 30(41.7) 0.637
Poor 26(59.1) 18(40.9)
Tumor diameter
≥ 40 mm 37(51.4) 35(48.6) 0.184
<40 mm 61(61.6) 38(38.4)
Depth of invasion
Submucosa 8(66.7) 4(33.3) 0.212
Muscularis propria 36(60.7) 22(39.3)
Adventitia 54(53.8) 47(46.2)
pT classification
T1~T2 41(69.5) 18(30.5) 0.019
T3~T4 57(50.9) 55(49.1)
pN classification
YES 38(49.4) 39(50.6) 0.057
NO 60(63.8) 34(36.2)
pMetastasis
YES 4(44.4) 5 (55.6) 0.426
NO 94(58.0) 68 (42.0)
*Stage I-II vs. III-IVBMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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lines and in immortalized nasopharyngeal epithelial cells
than in the normal nasopharyngeal epithelial cell line at
both transcriptional and translational levels. Importantly,
patients with higher CENP-H expression had shorter over-
all survival time, whereas patients with lower CENP-H
expression had better survival, and CENP-H expression
was an independent prognostic factor. These results indi-
cated an important role for CENP-H in the development
and progression of ESCC.
More and more kinetochore proteins have been shown to
be associated with carcinogenesis. CENP-F and INCENP
are upregulated in human cancer cells [28,29]. CENP-A
has been shown to be overexpressed in colorectal cancer
cells and is mistargeted to noncentromeric regions[30].
CENP-F has been implicated in malignancy [31,32], and
its expression is correlated with tumor size in node-nega-
tive breast cancer [33]. The CENP-F gene is amplified and
overexpressed in head and neck squamous cell carcinoma
[34]. A recent study has shown that increased CENP-F pro-
tein levels influence tumorigenesis at early stages of tumor
development [35]. These findings suggest that kineto-
chore proteins up-regulation is a common abnormality in
tumors.
Being consistent with our previous study, we found that
CENP-H was overexpressed in immortalized and ESCC
cell lines as well as in ESCC tissues both at transcriptional
and translational levels. We further analyzed the relation-
ship between the expression of CENP-H and clinical char-
acteristics of the patients. There was no significant
correlation between the expression of CENP-H and age,
histologic classification, histological differentiation,
tumor diameter, depth of invasion, pN classification or
distant metastasis of esophageal cancer patients. How-
ever, there was a significant relationship of CENP-H
expression in patients categorized according to stage (P =
0.023) and T classification (P = 0.019), strongly suggest-
ing that CENP-H can be used as a marker to identify sub-
sets of ESCC cancer patients with more aggressive disease.
In addition, our study suggested that the expression of
Kaplan-Meier curves with univariate analyses (log-rank) for  patients with low CENP-H expression (bold line) versus high  CENP-H expressing tumors (dotted line) Figure 4
Kaplan-Meier curves with univariate analyses (log-
rank) for patients with low CENP-H expression (bold 
line) versus high CENP-H expressing tumors (dotted 
line). The median survival of patients with high CENP-H 
expression was much shorter (19 months) than those with 
low CENP-H expression (33 months) (P < 0.001, Log-rank).
Table 3: Univariate and multivariate analysis of different prognostic parameters in patients with esophageal carcinoma by Cox-
regression analysis
Univariate analysis Multivariate analysis
No. patients p Regression coefficient(SE) p Relative risk 95% confidence interval
pN metastasis 0.592(0.197) 0.003 1.807 1.227~2.662
Yes 77 <0.001
No 94
Stage 0.039 -0.403 (0.293) 0.169 0.669 0.377~1.187
I-II 99
III-IV 72
Gender -0.496(0.259) 0.056 0.609 0.366~1.012
Male 129 0.005
Female 42
CENP-H 0.529(0.200) 0.008 1.698 1.147~2.513
Low expression 98 <0.001
High expression 73BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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Kaplan-Meier analysis showing the overall survival of esophageal carcinoma patients categorized according to the T or N classi- fication and status of CENP-H expression Figure 5
Kaplan-Meier analysis showing the overall survival of esophageal carcinoma patients categorized according to 
the T or N classification and status of CENP-H expression. The statistical significance of the difference between curves 
of CENP-H high-expressing and low-expressing patients was compared in T1–T2 (A) and T3–T4 (B) patient subgroups. The 
same analysis was compared in N0(C) and N1(D). P values were calculated by the log-rank test.BMC Cancer 2008, 8:233 http://www.biomedcentral.com/1471-2407/8/233
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CENP-H protein in male patients was higher than in
female patients. Generally, The female patients had better
survival, whereas the male patients had shorter survival
[39]. Our analysis showed the same result (data not
shown), in accordance with the relation analysis between
the expression of CENP-H protein and the overall survival
(Fig. 4). With regard to the correlation between immuno-
histochemical CENP-H staining and the prognosis of
esophageal carcinoma, we have shown in univariate and
multivariate analyses that high expression of CENP-H is
an independent prognosticator for patient survival of
esophageal cancer. We also analyzed higher CENP-H
expression had significantly shorter overall survival dur-
ing the T3~T4 patients subgroups. The pathological TNM
classification indicated that T classification was based on
the depth of invasion for carcinogenesis[20]. At the same
time, more and more kinetochore proteins have been
shown to be associated with carcinogenesis, including
CENP-A, CENP-F and INCENP. Shigeishi et al. [16,31]
reported CENP-H and CENP-F was closely linked to the
increased or abnormal cell proliferation in malignant con-
ditions. It suggests that overexpression of CENP-H might
be correlated with abnormal cell proliferation in ESCC. In
addition, we found that CENP-H might function as a new
prognostic marker in ESCC for the N0 patient subgroups,
because in these subgroups there is also a trend toward
shorter overall survival times of patients with high expres-
sion of CENP-H. The combination of pTNM classification
and CENP-H expression level in tumor cells is useful for
predicting the prognosis of patients with ESCC. Further
studies are clearly needed to verify these findings to estab-
lish CENP-H as a prognostic marker in ESCC and to clarify
its role in carcinogenesis by functional analysis.
These observations highlight the important role of CENP-
H in the development and progression of ESCC. As study
in colorectal cancer cell lines showed that overexpression
of CENP-H remarkably induced aneupoidy. Moreover,
CENP-H stable transfectant of mouse embryonic fibro-
last/3T3 cell lines showed aberrant interphase micronu-
clei, characteristic of chromosomes missegregation [15].
Other reports show that deletion of CENP-H results in an
accumulation of cells in metaphase and subsequent cell
death as a result of chromosome aberrations and misseg-
regation [38]. CENP-H is a component of active centro-
mere-kinetochore complexes in mammals, colocalizing
with both CENP-A and CENP-C, which are found in the
inner kinetochore plate throughout the cell cycle
[13,36,37]. Inappropriate expression of CENP-H might
deplete other centromere-kinetochore components and
disrupt the kinetochore complex, or prevent normal kine-
tochore assembly and consequently cause aneuploidy and
induce the development of cancer [22]. These results sug-
gest that CENP-H may be crucial for the appropriate local-
ization and the proper function of the kinetochore.
Chromosomal abnormalities, including abnormal chro-
mosome numbers, chromosome deletion, and amplifica-
tion, are commonly found in ESCC [23-25]. It was
reported that defects in mitotic checkpoints occur fre-
quently (~40%) in ESCC cells [26]. Evidence has shown
that chromosomal instability plays an important role in
the development and progression of ESCC because aneu-
ploidy is frequently found in the earliest stages of tumor-
igenesis [27]. Up-regulation of CENP-H in esophageal
cancer cells may contribute to chromosomal instability
and thus play a role in the progression of ESCC.
The development and progression of ESCC stages, includ-
ing single hyperplasia and single squamous metaplasia,
atypical hyperplasia and allotype squamous metaplasia,
in situ carcinoma, infiltrating carcinoma, and metastatic
carcinoma, may involve the accumulation of multiple
genetic alterations over a long period of time [40]. Cell
immortalization is the ability of normal cells to grow
through an in definite number of divisions in culture[41].
Because immortalized cells are capable of unlimited pro-
liferation and represent the early stage of transformation
before malignant transformation, we examined CENP-H
expression in immortalized esophageal epithelial cell line
NE3 and found that CENP-H protein was up-regulated in
NE3 cells (Fig. 1). These results suggest that CENP-H may
be an early transformation factor of esophageal epithelial
cells.
Conclusion
This is the first study showing the expression of CENP-H
in esophageal cancer cell lines as well as tumor tissues,
highlighting the clinical significance of CENP-H in
esophageal carcinoma. An examination of CENP-H
expression is a useful molecular marker for esophageal
carcinoma and an indicator for determining malignant
properties, including clinical outcome in patients with
esophageal carcinoma. However, further studies are
needed to clarify the mechanism by which CENP-H is
involved in the development and progression of esopha-
geal carcinoma and its exact role in the regulation of chro-
mosome instability in esophageal carcinoma.
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